Indacaterol once-daily is equally effective dosed in the evening or morning in COPD

Respiratory Medicine

Volumn 104, Issue 12, 2010, Pages 1869-1876

  Magnussen, H ^a   Verkindre, C ^b   Jack, D ^c   Jadayel, D ^c   Henley, M ^c   Woessner, R ^d   Higgins, M ^c   Kramer, B ^d  

^a KRANKENHAUS GROSSHANSDORF   (Germany)

^b Centre Hospitalier de Bethune   (France)

^c NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Chronic obstructive pulmonary disease; Evening dose; Indacaterol; Morning dose; Salmeterol

Indexed keywords

CORTICOSTEROID; INDACATEROL; PLACEBO; SALMETEROL;

ADULT; ARTICLE; BLINDNESS; BLOOD PRESSURE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; COUGHING; CROSSOVER PROCEDURE; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EVENING DOSAGE; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; MALE; MORNING DOSAGE; MULTICENTER STUDY; PRIORITY JOURNAL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT OUTCOME; WAKEFULNESS;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FORCED EXPIRATORY VOLUME; HUMANS; INDANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; TIME FACTORS;

EID: 78449303849     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2010.08.010     Document Type: Article

References (14)

1. WHO. World health statistics http://www.who.int/whosis/whostat/2008/en/ index.html 2008 Date last accessed 04.06.10
2. J.B. Soriano, G.T. Visick, H. Muellerova, N. Payvandi, and A.L. Hansell Patterns of comorbidities in newly diagnosed COPD and asthma in primary care Chest 128 4 2005 Oct 2099 2107
3. J. Yeo, G. Karimova, and S. Bansal Co-morbidity in older patients with COPD-its impact on health service utilisation and quality of life, a community study Age Ageing 35 1 2006 Jan 33 37
4. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease Updated 2009 http://www.goldcopd.org
5. J. Beier, P. Chanez, J.B. Martinot, A.J. Schreurs, R. Tkacova, and W. Bao Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial Pulm Pharmacol Ther 20 6 2007 740 749
6. S. Rennard, K.R. Chapman, A. Luthra, J. Swales, C. Lassen, and R. Owen Once-daily indacaterol provides effective bronchodilation over 1 year of treatment in patients with chronic obstructive pulmonary disease (COPD) Chest 136 4 2009 4S
7. J. Vestbo, R. Pauwels, J.A. Anderson, P. Jones, and P. Calverley Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease Thorax 60 4 2005 Apr 301 304
8. O. Kornmann, R. Dahl, S. Centanni, A. Dogra, R. Owen, and C. Lassen Once-daily indacaterol vs twice-daily salmeterol for COPD: a placebo-controlled comparison Eur Respir J 2010 10.1183/09031936.00045810 Epub ahead of print Aug 6, 2010
9. C. LaForce, J. Aumann, L. de Teresa Parreño, A. Iqbal, D. Young, and R. Owen Sustained 24-h efficacy of once daily indacaterol (300 mug) in patients with chronic obstructive pulmonary disease: a randomized, crossover study Pulm Pharmacol Ther 2010 10.1016/j.pupt.2010.06.005 Epub ahead of print 07.07.10
10. P.M. Calverley, A. Lee, L. Towse, J. van Noord, T.J. Witek, and S. Kelsen Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease Thorax 58 10 2003 Oct 855 860
11. J.F. Donohue, C. Fogarty, J. Lotvall, D.A. Mahler, H. Worth, and A. Yorgancioglu Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium Am J Respir Crit Care Med 182 2010 155 162
12. C. Vogelmeier, D. Ramos-Barbon, D. Jack, S. Piggott, R. Owen, and M. Higgins Once-daily indacaterol provides effective 24-hour bronchodilation in chronic obstructive pulmonary disease (COPD): a double-blind comparison with tiotropium Chest 136 2009 4S
13. S. Pascoe, C. Reynolds, W. Pleskow, S. Perry, A. Hmissi, and L. Brookman Safety and tolerability of single therapeutic and supratherapeutic doses of indacaterol in patients with chronic obstructive pulmonary disease (COPD) Am J Respir Crit Care Med 175 2007 A128
14. R. Dahl, K.F. Chung, R. Buhl, H. Magnussen, V. Nonikov, and D. Jack Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD Thorax 65 6 2010 Jun 473 479